SEELOS THERAPEUTICS, INC. (APRI) [Rocket]

Overview

SEELOS THERAPEUTICS, INC. (APRI)

Add to portfolio

1m \| 3m \| 6m \| 1y \| 2y \| 5y \| 10y

Recent News + Filings (All items)

Date Filed	Type	Description
10/02/2023	8-K	Quarterly results
10/02/2023	EFFECT	Form EFFECT - Notice of Effectiveness:
09/29/2023	424B3	Form 424B3 - Prospectus [Rule 424(b)(3)]:
08/11/2023	10-Q	Quarterly Report for the period ended June 30, 2023
06/29/2023	8-K	Other Events  Interactive Data
05/19/2023	8-K	Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modifications to Rights of Secu...
04/28/2023	DEFA14A	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:

Revenue Mix by Segment

Financial Summary (All financials)

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15	Dec-31-14
Revenues	0.0	0.0	0.4	0.0	0.0	0.0	4.8	9.3
Revenue growth		-100.0%				-100.0%	-47.7%	268.7%
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.9
Gross profit	0.0	0.0	0.4	0.0	0.0	0.0	3.9	8.3
Gross margin			100.0%				80.9%	90.1%
Research and development	46.6	11.0	22.6	0.6	3.5	5.9	14.6	21.3
General and administrative	15.0	7.8	7.6	2.6	7.2	7.8	10.5	11.4
EBIT	-61.7	-18.8	-46.2	-3.2	-10.7	-13.7	-21.4	-23.4
EBIT margin			-12332.8%				-441.2%	-252.8%
Pre-tax income	-66.0	-19.1	-51.3	-3.5	-11.7	-7.7	-19.0	-22.5
Income taxes	0.0	0.0	0.0	0.0	-12.1	-0.2	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	102.7%	3.0%	0.0%	0.0%
Earnings from continuing ops	-66.0	-19.1	-51.3	-3.5	-11.7	-7.7	-19.0	-22.5
Earnings from discontinued ops								0.7
Net income	-66.0	-19.1	-51.3	-3.5	0.3	-7.4	-19.0	-21.8
Net margin			-13668.0%				-393.1%	-235.3%

Diluted EPS	($0.73)	($0.43)	($2.52)	($1.13)	($29.67)	($1.18)	($3.83)	($0.57)
Shares outstanding (diluted)	90.9	44.8	20.3	3.1	0.4	6.5	5.0	39.5

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.